4th Quarter - Report

VIATRIS INC. for VIATRIS INC

Period 4th Quarter 2011 Filed Jan 20, 2012 Signed by Lara Ramsburg, VP Government Relations

Official filing
Firm
VIATRIS INC.
Client
VIATRIS INC
Income
—
Expenses
$450,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Authorized Generics; User Fees; Drug Shortages; Patent Settlements; Food, Drug, and Cosmetic Act (FDCA); Serialization; Access to epinephrine auto-injectors in an emergency; Issues relating to HIV/AIDS, funding for Antiretrovirals (ARVs), PEPFAR, Global Fund; Issues relating to biosimilars; Issues related to the generic drug industry; Issues related to Average Manufacturer Price (AMP); Globalizing the FDA

LobbyistCovered position, as disclosed
BRUCE LOTT —
LARA RAMSBURG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Medicaid reimbursement

LobbyistCovered position, as disclosed
BRUCE LOTT —
LARA RAMSBURG —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Patent settlements and patent reform legislation

LobbyistCovered position, as disclosed
LARA RAMSBURG —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.